Blueprint Medicines Shares 2025 Outlook and Strategic Plans for Sustained Growth
Blueprint Medicines Corporation recently unveiled its 2025 corporate outlook and strategic vision for sustained growth, leveraging its established research, development, and commercial expertise. According to Kate Haviland, Chief Executive Officer…
Pharma Partners Gilead and LEO Pharma to Accelerate Oral STAT6 Program for Inflammatory Diseases
Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership…
Pharmaceutical Supply Chain Initiative Proudly Welcomes WuXi AppTec as Strategic Partner
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative to Strengthen Responsible Practices and Supply Chain Resilience Pharmaceutical Supply WuXi AppTec, a global leader providing comprehensive research, development, and manufacturing services…
Alnylam Strongly Reports Q4 2024 Revenues, 2025 Revenue Guidance, and Ambitious Pipeline Goals
Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth…
Ascendis Pharma Unveils Bold Strategic Update at J.P. Morgan Healthcare Conference
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President…
Heart Failure Bayer Files FDA and CDE Applications for Finerenone’s New Indication
Introduction to Heart Failure and the Need for New Treatments Bayer has announced that it has submitted marketing authorization applications to both the U.S. Food and Drug Administration (FDA) and…
Regenerative Medicine Breakthroug Bio-Techne Expands AI-Engineered Protein Portfolio for Cell Therapy
Regenerative Medicine Revolutionary Technologies Behind the Innovation Bio-Techne a renowned global leader in life science tools and reagents, has unveiled an impressive expansion to its R&D Systems AI-engineered designer protein…
Osimertinib Compared to RYBREVANT® + LAZCLUZE™ Significant and Promising Survival Benefit Observed
Osimertinib: A Benchmark in Targeted Therapy Osimertinib The European Commission has granted approval for the combination of RYBREVANT® (amivantamab) and LAZCLUZE® (lazertinib) for the first-line treatment of adult patients with…
Promising Formulation of New Sarclisa Subcutaneous Treatment Meets Co-Primary Endpoints in IRAKLIA Phase 3
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous…
Biologics License Grifols Submits Application to U.S. FDA for Innovative Fibrinogen Solution
Biologics License Grifols Advances Fibrinogen Solution with U.S. FDA Submission Biologics License Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, has announced the submission of a Biologics…
Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics
Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license…
Poseida Therapeutics Roche Acquires Majority Shares in Tender Offer
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender…